Unal A, Kocyigit I, Sipahioglu M H, Tokgoz B, Kavuncuoglu F, Oymak O, Utas C
Erciyes University Medical School, Department of Nephrology, Kayseri, 38039 Turkey.
Transplant Proc. 2010 Nov;42(9):3550-3. doi: 10.1016/j.transproceed.2010.07.106.
AIM: This study investigated the prevalence and contributing factors of loss of bone mineral density after renal transplantation among Turkish patients. PATIENTS AND METHODS: The study included 70 subjects, namely 50 males and 20 females of overall mean age of 36.94 ± 10.09 years. We measured femoral neck mineral density by dual-energy X-ray absorptiometry (DEXA). A T score above -1 was defined as a normal bone mineral density compared with T scores of -1.0 to -2.5 or below -2.5 which were defined as either osteopenia or osteoporosis, respectively. RESULTS: At a median duration of 23 months after renal transplantation, osteopenia or osteoporosis was observed among 30 (42.9%) or 30 (42.9%) of the 70 patients, respectively. The mean body mass index (BMI) value was significantly higher among the normal than the osteoporotic group: 27.59 ± 4.66 kg/m(2) vs 24.18 ± 3.57 kg/m(2), respectively. However, no significant differences occurred in terms of BMI among the other groups. The amount of proteinuria was significantly lower in the normal than the osteopenic or osteoporotic group: (12.5 (range, 10.0-20.0); 105.0 (10.0-2800.0) or 215.5 (10.0-1880.0) mg/d (P = .001 and .004, respectively). In contrast, there was no significant difference between the amounts of proteinuria displayed by the osteopenic group and the osteoporotic group (P < .05)]. These patient groups showed no difference in age, gender, donor source, cause of end-stage renal disease (ESRD), pretransplant dialysis modality, duration of dialysis, use of a vitamin D preparation, immunosuppressive regimen, posttransplantation period, levels of iPTH or 25 hydroxy vitamin D3 (25OH vit D), exposure to tacrolimus or cyclosporine (CyA), calcium × phosphate product, serum albumin and hemoglobin content, creatinine clearance, or serum bicarbonate concentrations (P > .05). The T scores of the femoral neck correlated with BMI (r: 0.415; P = .001), 25OH vit D level (r: 0.268, P = .026), creatinine clearance (r: 0.273, P = .022), and serum glucose level (r: 0.349, P = .003). It inversely correlated with the amount of proteinuria (r: -0.263, P = .028), serum alkaline phosphatase level (r: -0.329, P = .005), and serum magnesium concentration (r: -0.252, P = .035). Upon multivariate analysis, BMI and 25OH vit D level were observed to be independent risk factors for loss of femoral mineral density. CONCLUSION: Loss of bone mineral density is a common complication that correlates with low BMI values and decreased 25OH vit D levels as major risk factors for this problem.
目的:本研究调查了土耳其肾移植患者骨矿物质密度丧失的患病率及相关因素。 患者与方法:该研究纳入了70名受试者,即50名男性和20名女性,总体平均年龄为36.94±10.09岁。我们采用双能X线吸收法(DEXA)测量股骨颈矿物质密度。与T值-1.0至-2.5或低于-2.5相比,T值高于-1被定义为正常骨矿物质密度,后两者分别被定义为骨质减少或骨质疏松。 结果:肾移植术后中位时间为23个月时,70例患者中分别有30例(42.9%)出现骨质减少或骨质疏松。正常组的平均体重指数(BMI)值显著高于骨质疏松组:分别为27.59±4.66kg/m²和24.18±3.57kg/m²。然而,其他组之间的BMI无显著差异。正常组的蛋白尿水平显著低于骨质减少组或骨质疏松组:分别为12.5(范围10.0 - 20.0);105.0(10.0 - 2800.0)或215.5(10.0 - 1880.0)mg/d(P分别为0.001和0.004)。相比之下,骨质减少组和骨质疏松组的蛋白尿水平无显著差异(P < 0.05)。这些患者组在年龄、性别、供体来源、终末期肾病(ESRD)病因、移植前透析方式、透析时间、维生素D制剂的使用、免疫抑制方案、移植后时间、甲状旁腺激素(iPTH)或25羟维生素D3(25OH vit D)水平、他克莫司或环孢素(CyA)暴露、钙×磷乘积、血清白蛋白和血红蛋白含量、肌酐清除率或血清碳酸氢盐浓度方面均无显著差异(P > 0.05)。股骨颈的T值与BMI(r:0.415;P = 0.001)、25OH vit D水平(r:0.268,P = 0.026)、肌酐清除率(r:0.273,P = 0.022)和血糖水平(r:0.349,P = 0.003)相关。它与蛋白尿水平(r:-0.263,P = 0.028)、血清碱性磷酸酶水平(r:-0.329,P = 0.005)和血清镁浓度(r:-0.252,P = 0.035)呈负相关。多因素分析显示,BMI和25OH vit D水平是股骨矿物质密度丧失的独立危险因素。 结论:骨矿物质密度丧失是一种常见并发症,与低BMI值和25OH vit D水平降低相关,是该问题的主要危险因素。
Transplant Proc. 2010-11
Iran J Kidney Dis. 2017-10
Toxins (Basel). 2020-11-13
J Bone Miner Metab. 2016-3
Transl Med UniSa. 2013-1-4